Physician profile
Sarah E Smith
NPI 1215288584
$1,526.02
in general payments reported to CMS, 2019-2025
27 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $292 · 2023: $368 · 2024: $280 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $380.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $160.81 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Alexion Pharmaceuticals, INC. | $103.71 | 2021-2023 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.38 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.13 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $76.00 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $67.39 | 2021-2024 | |
| Pfizer INC. | $61.02 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $56.82 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $43.84 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $39.56 | 2022-2025 | Shingrix |
| Impel Pharmaceuticals INC. | $35.19 | 2023 | Trudhesa |
| Gilead Sciences, INC. | $33.29 | 2024 | |
| Exact Sciences Corporation | $25.87 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $25.42 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $23.12 | 2023 | |
| Astellas Pharma US INC | $22.21 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $21.31 | 2023 | Gvoke Hypopen |
| Seqirus USA INC | $18.77 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Inspire Medical Systems, INC. | $18.68 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.36 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.33 | 2024 | Voquezna |
| Upsher-Smith Laboratories LLC | $18.11 | 2022 | |
| Novo Nordisk INC | $17.69 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.37 | 2024 | Austedo Xr |
| Lilly USA, LLC | $15.48 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.